# A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

> **NCT01116895** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 63 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 22811
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01116895
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-03
- **Final completion:** 2011-07
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01116895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01116895, "A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01116895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*